A Phase 3 interventional study of peginterferon alfa-2a [Pegasys] and peginterferon alfa-2a [Pegasys] in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 39 sites in 12 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-11-18.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 20th largest by enrollment, is one of 4 that started in 2012, is one of 11 in phase 3, and was the 27th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:
IntegerBio · Sites in Hong Kong, Moldova, New Zealand and 1 more country
Ages 18–70 · Healthy volunteers
By country, each count listing its studies:
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 12 · Phase 4 29
First in 2002; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 114 across the 59 interventional studies. Of the 39 that completed or were terminated, 17 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 59 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
46 studies in Hepatitis B, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 45 finished, 25 (56%) have results posted.
Among the 46 studies in Hepatitis B, Chronic by Hoffmann-La Roche, this one is the 12th largest by enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2012, is one of 7 in phase 3, and was the 20th registered.
Hoffmann-La Roche’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing peginterferon alfa-2a in Hepatitis B, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389044IntegerBioA Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 46 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This parallel group, open label study will evaluate the safety and efficacy of Pegasys (peginterferon alfa-2a) versus untreated control in children (age 3 years to \<18 years at baseline) with HBeAg positive chronic hepatitis B. Children without advanced fibrosis and without cirrhosis will be randomized 2:1 to treatment Group A, receiving Pegasys 45-180 mcg subcutaneously weekly for 48 weeks, or to the untreated control Group B. Children with advanced fibrosis will be assigned to treatment group C and receive 48 weeks of treatment with Pegasys. Children in the untreated control Group B who have not experienced seroconversion 48 weeks after randomization may enter the Switch Arm to receive 48 weeks of Pegasys treatment. This offer will be available for 1 year following 48 weeks from randomization. Anticipated time on study treatment is 48 weeks. All subjects will be followed up for 5 years after the end of treatment (A,C,Switch)/principal observation (B) period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: peginterferon alfa-2a [Pegasys]
Drug: peginterferon alfa-2a [Pegasys]
Drug: peginterferon alfa-2a [Pegasys]
Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
Percentage of Participants With HBeAg Seroconversion at 24 Weeks After End of Treatment (EOT)/POP in Groups A and B
HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Loss of HBeAg at 24 Weeks After EOT/POP in Groups A and B
The percentage of participants with loss of HBeAg at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion at 24 Weeks After EOT/POP in Groups A and B
HBsAg seroconversion was defined as loss of HBsAg and the presence of hepatitis B surface antibody (anti-HBs). The percentage of participants with HBsAg seroconversion at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Normal ALT at 24 Weeks After EOT/POP in Groups A and B
Normal ALT was defined as ALT less than or equal to (≤) ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After EOT/POP in Groups A and B
HBV DNA was quantified using polymerase chain reaction (PCR) by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBeAg Seroconversion at EOT/POP in Groups A and B
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: Week 48
Percentage of Participants With Loss of HBeAg at EOT/POP in Groups A and B
The percentage of participants with loss of HBeAg at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: Week 48
Percentage of Participants With HBsAg Seroconversion at EOT/POP in Groups A and B
HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: Week 48
Percentage of Participants With Loss of HBsAg at EOT/POP in Groups A and B
The percentage of participants with loss of HBsAg at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: Week 48
Percentage of Participants With Normal ALT at EOT/POP in Groups A and B
Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: Week 48
Percentage of Participants With HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: Week 48
Percentage of Participants With HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: Week 48
Percentage of Participants With HBV DNA Undetectable at EOT/POP in Groups A and B
HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: Week 48
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: Week 48
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: Week 48
Quantitative Serum ALT Level in Groups A and B
Quantitative ALT at each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). ITT Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Quantitative HBV DNA Level in Groups A and B
Quantitative HBV DNA at each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Baseline; Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Change From Baseline in Quantitative HBV DNA Level in Groups A and B
The change in quantitative HBV DNA from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Percentage of Participants With Loss of HBeAg at 24 Weeks After EOT in Group C
The percentage of participants with loss of HBeAg at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population: All participants who received at least one dose of study drug (if assigned) and had at least one post-baseline safety assessment.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBsAg Seroconversion at 24 Weeks After EOT in Group C
HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Loss of HBsAg at 24 Weeks After EOT in Group C
The percentage of participants with loss of HBsAg at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Normal ALT at 24 Weeks After EOT in Group C
Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBV DNA Undetectable at 24 Weeks After EOT in Group C
HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBeAg Seroconversion at EOT in Group C
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: Week 48
Percentage of Participants With Loss of HBeAg at EOT in Group C
The percentage of participants with loss of HBeAg at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: Week 48
Percentage of Participants With HBsAg Seroconversion at EOT in Group C
HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: Week 48
Percentage of Participants With Loss of HBsAg at EOT in Group C
The percentage of participants with loss of HBsAg at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: Week 48
Percentage of Participants With Normal ALT at EOT in Group C
Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: Week 48
Percentage of Participants With HBV DNA <20,000 IU/mL at EOT in Group C
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: Week 48
Percentage of Participants With HBV DNA <2,000 IU/mL at EOT in Group C
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: Week 48
Percentage of Participants With HBV DNA Undetectable at EOT in Group C
HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: Week 48
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT in Group C
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: Week 48
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT in Group C
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: Week 48
Quantitative Serum ALT Level in Group C
Quantitative ALT at each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Quantitative HBV DNA Level in Group C
Quantitative HBV DNA at each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Baseline; Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Change From Baseline in Quantitative HBV DNA Level in Group C
The change in quantitative HBV DNA from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Weeks 12, 24, 36, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Estimated Area Under the Concentration-Time Curve (AUC) by BSA Category
AUC was estimated using population pharmacokinetic (PK) modeling. The AUC at steady-state was averaged among participants who received PEG-IFN and reported by BSA category. Categories of BSA-based dosing used in the analysis were as follows: 0.54-0.74 m\^2, 65 mcg; 0.75-1.08 m\^2, 90 mcg; 1.09-1.51 m\^2, 135 mcg; \>1.51 m\^2, 180 mcg. The estimated AUC was expressed in hours by nanograms per milliliter (h\*ng/mL). PK Substudy Population: All participants who consented to participate in the PK substudy. "Number of subjects analyzed" reflects the total combined number of participants who provided evaluable data across all BSA categories. The number of participants who provided evaluable data within each BSA category (n) is shown in the table.
Time frame: Pre-dose (0 hours) at Baseline and Weeks 4, 8, 12, 24; post-dose (24-48, 72-96, 168 hours) during Weeks 1, 24 (up to 24 weeks overall)
Percentage of Participants With >15% Drop in Height Percentile for Age in Groups A and B
The percentage of participants with \>15% drop in height percentile for age from Baseline to each visit was reported. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Weeks 12, 24, 36, 48; FU Weeks 12, 24 (up to 72 weeks overall)
Percentage of Participants With >15% Drop in Weight Percentile for Age in Groups A and B
The percentage of participants with \>15% drop in weight percentile for age from Baseline to each visit was reported. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Weeks 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Quantitative HBeAg Level in Groups A and B
Quantitative HBeAg at each visit was averaged among all participants and expressed in log10 Paul Ehrlich Institute units per milliliter (PEIU/mL). ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Quantitative HBsAg Level in Groups A and B
Quantitative HBsAg at each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Quantitative HBeAg Level in Group C
Quantitative HBeAg at each visit was averaged among all participants and expressed in log10 PEIU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Quantitative HBsAg Level in Group C
Quantitative HBsAg at each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population.
Time frame: Baseline; Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Change From Baseline in Liver Stiffness Measure (LSM) in Groups A, B, C
Liver elastography was performed to assess elasticity and extent of hepatic fibrosis. The change in LSM from Baseline to each visit was averaged among all participants in expressed in kilopascals (kPa). Positive changes in LSM values corresponded to an increase in stiffness and hepatic fibrosis. Liver Substudy Population: All participants who consented to participate in the liver elasticity substudy. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Week 48; FU Week 24 (up to 72 weeks overall)
Percentage of Participants With >15% Drop in Height Percentile for Age in Group C
The percentage of participants with \>15% drop in weight percentile for age from Baseline to each visit was reported. Safety Population.
Time frame: Weeks 30, 36; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Change From Baseline in Height for Age Z-Score in Groups A and B
The difference between the population mean and raw scores was calculated as the height for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Baseline; Weeks 12, 24, 36, 48; FU Weeks 12, 24 (up to 72 weeks overall)
Change From Baseline in Weight for Age Z-Score in Groups A and B
The difference between the population mean and raw scores was calculated as the weight for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations.Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Change From Baseline in Height for Age Z-Score in Group C
The difference between the population mean and raw scores was calculated as the height for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population.
Time frame: Baseline; Weeks 12, 24, 36, 48; FU Weeks 12, 24 (up to 72 weeks overall)
Change From Baseline in Weight for Age Z-Score in Group C
The difference between the population mean and raw scores was calculated as the weight for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Percentage of Participants With HBeAg Seroconversion at 24 Weeks After EOT in Group C
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Change From Baseline in Quantitative Serum ALT Level in Groups A and B
The change in quantitative ALT from Baseline to each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Change From Baseline in Quantitative HBeAg Level in Groups A and B
The change in quantitative HBeAg from Baseline to each visit was averaged among all participants and expressed in log10 PEIU/mL. ITT Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Change From Baseline in Quantitative HBsAg Level in Groups A and B
The change in quantitative HBsAg from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Change From Baseline in Quantitative Serum ALT Level in Group C
The change in quantitative ALT from Baseline to each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Weeks 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48; FU Weeks 4, 12, 24 (up to 72 weeks overall)
Change From Baseline in Quantitative HBeAg Level in Group C
The change in quantitative HBeAg from Baseline to each visit was averaged among all participants and expressed in log10 PEIU/mL. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
Time frame: Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Change From Baseline in Quantitative HBsAg Level in Group C
The change in quantitative HBsAg from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population.
Time frame: Weeks 12, 24, 36, 48; FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBeAg Seroconversion Over Time in Groups A and B
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: Baseline, FU Years: 1, 2, 3, 4, 5
Percentage of Participants With Loss of HBeAg at 24 Weeks After the End of Switch Treatment Period: Switch Group
The percentage of participants with loss of HBeAg at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBsAg Seroconversion at 24 Weeks After the End of Switch Treatment Period: Switch Group
HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Loss of HBsAg at 24 Weeks After the End of Switch Treatment Period: Switch Group
HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Normal ALT at 24 Weeks After the End of Switch Treatment Period: Switch Group
Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After the End of Switch Treatment Period: Switch Group
HBV DNA was quantified using polymerase chain reaction (PCR) by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With HBV DNA Undetectable at 24 Weeks After the End of Switch Treatment Period: Switch Group
HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
Time frame: FU Week 24 (up to 72 weeks overall)
| Milestone | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|---|---|
| Started | 101 | 50 | 10 |
| Completed week 48 | 99 | 47 | 10 |
| Completed follow-up (fu) week 12 | 99 | 26 | 10 |
| Completed fu week 24 | 99 | 15 | 10 |
| Completed fu 5 year | 75 | 28 | 5 |
| Switch group | 0 | 33 | 0 |
| Completed | 75 | 28 | 5 |
| Not completed | 26 | 22 | 5 |
| Withdrew: Withdrawal from the study | 26 | 22 | 5 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With HBeAg Seroconversion at 24 Weeks After End of Treatment (EOT)/POP in Groups A and B | 25.7 ± 17.56 | 6 ± 1.25 |
The percentage of participants with loss of HBeAg at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With Loss of HBeAg at 24 Weeks After EOT/POP in Groups A and B | 25.7 ± 17.56 | 6 ± 1.25 |
HBsAg seroconversion was defined as loss of HBsAg and the presence of hepatitis B surface antibody (anti-HBs). The percentage of participants with HBsAg seroconversion at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion at 24 Weeks After EOT/POP in Groups A and B | 7.9 ± 3.48 | 0 ± 0 |
Normal ALT was defined as ALT less than or equal to (≤) ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With Normal ALT at 24 Weeks After EOT/POP in Groups A and B | 51.5 ± 41.33 | 12 ± 4.53 |
HBV DNA was quantified using polymerase chain reaction (PCR) by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After EOT/POP in Groups A and B | 33.7 ± 24.56 | 4 ± 0.49 |
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B | 28.7 ± 20.15 | 2 ± 0.05 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B | 22.8 ± 15.02 | 4 ± 0.49 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT/POP in Groups A and B | 19.8 ± 12.54 | 2 ± 0.05 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With HBeAg Seroconversion at EOT/POP in Groups A and B | 7.9 ± 3.48 | 6 ± 1.25 |
The percentage of participants with loss of HBeAg at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With Loss of HBeAg at EOT/POP in Groups A and B | 8.9 ± 4.16 | 6 ± 1.25 |
HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With HBsAg Seroconversion at EOT/POP in Groups A and B | 6.9 ± 2.83 | 0 ± 0 |
The percentage of participants with loss of HBsAg at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With Loss of HBsAg at EOT/POP in Groups A and B | 10.9 ± 5.56 | 0 ± 0 |
Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With Normal ALT at EOT/POP in Groups A and B | 18.8 ± 11.72 | 22 ± 11.53 |
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B | 36.6 ± 27.27 | 12 ± 4.53 |
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B | 30.7 ± 21.9 | 2 ± 0.05 |
HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With HBV DNA Undetectable at EOT/POP in Groups A and B | 18.8 ± 11.72 | 0 ± 0 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT/POP in Groups A and B | 6.9 ± 2.83 | 6 ± 1.25 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT/POP in Groups A and B | 6.9 ± 2.83 | 0 ± 0 |
Quantitative ALT at each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). ITT Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| factor of ULN | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Baseline | 2.779 ± 2.483 | 2.878 ± 1.997 |
| Week 1 | 3.427 ± 2.687 | — |
| Week 2 | 2.846 ± 1.885 | — |
| Week 4 | 3.343 ± 2.455 | — |
| Week 8 | 3.262 ± 2.797 | — |
| Week 12 | 3.189 ± 3.06 | — |
| Week 18 | 3.036 ± 2.389 | — |
| Week 24 | 2.753 ± 2.725 | 2.401 ± 2.638 |
| Week 30 | 2.587 ± 2.128 | — |
| Week 36 | 2.45 ± 1.856 | 2.341 ± 2.204 |
| Week 42 | 2.316 ± 1.429 | — |
| Week 48 | 2.122 ± 1.389 | 1.954 ± 1.371 |
| FU Week 4 | 1.303 ± 1.74 | — |
| FU Week 12 | 2.064 ± 2.027 | — |
| FU Week 24 | 1.477 ± 1.625 | 1.7 ± 1.385 |
Quantitative HBV DNA at each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| log10 IU/mL | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Baseline | 8.094 ± 0.986 | 8.056 ± 0.987 |
| Week 12 | 6.49 ± 2.009 | 7.909 ± 1.267 |
| Week 24 | 5.966 ± 2.398 | 7.857 ± 1.327 |
| Week 36 | 5.575 ± 2.513 | 7.685 ± 1.608 |
| Week 48 | 5.224 ± 2.701 | 7.551 ± 1.761 |
| FU Week 4 | 5.739 ± 2.935 | — |
| FU Week 12 | 5.914 ± 3.065 | 7.214 ± 2.46 |
| FU Week 24 | 5.707 ± 3.113 | 7.2 ± 2.506 |
The change in quantitative HBV DNA from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| log10 IU/mL | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Week 12 | -1.588 ± 1.625 | -0.156 ± 1.093 |
| Week 24 | -2.112 ± 1.996 | -0.168 ± 1.214 |
| Week 36 | -2.525 ± 2.148 | -0.359 ± 1.411 |
| Week 48 | -2.877 ± 2.374 | -0.493 ± 1.518 |
| FU Week 4 | -2.34 ± 2.582 | — |
| FU Week 12 | -2.164 ± 2.737 | -0.86 ± 2.163 |
| FU Week 24 | -2.381 ± 2.778 | -0.587 ± 2.259 |
The percentage of participants with loss of HBeAg at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population: All participants who received at least one dose of study drug (if assigned) and had at least one post-baseline safety assessment.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With Loss of HBeAg at 24 Weeks After EOT in Group C | 30 ± 6.67 |
HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With HBsAg Seroconversion at 24 Weeks After EOT in Group C | 0 ± 0 |
The percentage of participants with loss of HBsAg at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With Loss of HBsAg at 24 Weeks After EOT in Group C | 0 ± 0 |
Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With Normal ALT at 24 Weeks After EOT in Group C | 70 ± 34.75 |
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C | 70 ± 34.75 |
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C | 70 ± 34.75 |
HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With HBV DNA Undetectable at 24 Weeks After EOT in Group C | 30 ± 6.67 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After EOT in Group C | 30 ± 6.67 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After EOT in Group C | 30 ± 6.67 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With HBeAg Seroconversion at EOT in Group C | 20 ± 2.52 |
The percentage of participants with loss of HBeAg at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With Loss of HBeAg at EOT in Group C | 20 ± 2.52 |
HBsAg seroconversion was defined as loss of HBsAg and the presence of anti-HBs. The percentage of participants with HBsAg seroconversion at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With HBsAg Seroconversion at EOT in Group C | 0 ± 0 |
The percentage of participants with loss of HBsAg at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With Loss of HBsAg at EOT in Group C | 0 ± 0 |
Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With Normal ALT at EOT in Group C | 40 ± 12.16 |
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With HBV DNA <20,000 IU/mL at EOT in Group C | 40 ± 12.16 |
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With HBV DNA <2,000 IU/mL at EOT in Group C | 30 ± 6.67 |
HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With HBV DNA Undetectable at EOT in Group C | 20 ± 2.52 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<20,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at EOT in Group C | 20 ± 2.52 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at EOT in Group C | 20 ± 2.52 |
Quantitative ALT at each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| factor of ULN | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Baseline | 2.804 ± 1.118 |
| Week 1 | 3.117 ± 1.322 |
| Week 2 | 2.896 ± 1.304 |
| Week 4 | 2.444 ± 1.727 |
| Week 8 | 2.703 ± 2.035 |
| Week 12 | 2.793 ± 1.288 |
| Week 18 | 2.215 ± 1.032 |
| Week 24 | 1.887 ± 1.095 |
| Week 30 | 2.22 ± 1.553 |
| Week 36 | 2.172 ± 1.09 |
| Week 42 | 1.593 ± 0.516 |
| Week 48 | 1.645 ± 1.242 |
| FU Week 4 | 1.136 ± 0.506 |
| FU Week 12 | 1.521 ± 0.755 |
| FU Week 24 | 1.549 ± 1.595 |
Quantitative HBV DNA at each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| log10 IU/mL | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Baseline | 7.866 ± 0.977 |
| Week 12 | 5.782 ± 1.771 |
| Week 24 | 5.599 ± 2.386 |
| Week 36 | 5.2 ± 2.451 |
| Week 48 | 5.319 ± 2.747 |
| FU Week 4 | 4.604 ± 2.442 |
| FU Week 12 | 4.252 ± 2.596 |
| FU Week 24 | 3.694 ± 3.127 |
The change in quantitative HBV DNA from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| log10 IU/mL | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Week 12 | -2.084 ± 1.1 |
| Week 24 | -2.267 ± 1.595 |
| Week 36 | -2.529 ± 1.879 |
| Week 48 | -2.546 ± 2.14 |
| FU Week 4 | -3.262 ± 2.102 |
| FU Week 12 | -3.613 ± 2.519 |
| FU Week 24 | -4.15 ± 2.904 |
AUC was estimated using population pharmacokinetic (PK) modeling. The AUC at steady-state was averaged among participants who received PEG-IFN and reported by BSA category. Categories of BSA-based dosing used in the analysis were as follows: 0.54-0.74 m\^2, 65 mcg; 0.75-1.08 m\^2, 90 mcg; 1.09-1.51 m\^2, 135 mcg; \>1.51 m\^2, 180 mcg. The estimated AUC was expressed in hours by nanograms per milliliter (h\*ng/mL). PK Substudy Population: All participants who consented to participate in the PK substudy. "Number of subjects analyzed" reflects the total combined number of participants who provided evaluable data across all BSA categories. The number of participants who provided evaluable data within each BSA category (n) is shown in the table.
| h*ng/mL | All Groups Combined |
|---|---|
| 0.54-0.74 m^2 | 3320 (633 to 5064) |
| 0.75-1.08 m^2 | 4037 (1897 to 6916) |
| 1.09-1.51 m^2 | 2765 (1750 to 4392) |
| >1.51 m^2 | 3448 (1914 to 5000) |
The percentage of participants with \>15% drop in height percentile for age from Baseline to each visit was reported. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Week 12 | 1 | 0 |
| Week 24 | 5 | 8.5 |
| Week 36 | 4 | 4.2 |
| Week 48 | 6.1 | 2.1 |
| FU Week 12 | 10.9 | 4.2 |
| FU Week 24 | 12 | 6.7 |
The percentage of participants with \>15% drop in weight percentile for age from Baseline to each visit was reported. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| percentage of participants | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Week 4 | 2 | — |
| Week 8 | 5 | — |
| Week 12 | 5.1 | 2.1 |
| Week 18 | 8.1 | — |
| Week 24 | 16 | 8.5 |
| Week 30 | 13.1 | — |
| Week 36 | 11.3 | 8.3 |
| Week 42 | 13.1 | — |
| Week 48 | 12.5 | 8.5 |
| FU Week 4 | 8.1 | — |
| FU Week 12 | 6.9 | 20.8 |
| FU Week 24 | 11 | 20 |
Quantitative HBeAg at each visit was averaged among all participants and expressed in log10 Paul Ehrlich Institute units per milliliter (PEIU/mL). ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| log10 PEIU/mL | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Baseline | 2.736 ± 0.502 | 2.568 ± 0.65 |
| Week 12 | 2.09 ± 0.879 | 2.391 ± 0.878 |
| Week 24 | 1.865 ± 0.956 | 2.36 ± 0.896 |
| Week 36 | 1.604 ± 0.991 | 2.272 ± 0.985 |
| Week 48 | 1.466 ± 1.053 | 2.124 ± 1.091 |
| FU Week 24 | 1.537 ± 1.334 | 2.217 ± 1.395 |
Quantitative HBsAg at each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| log10 IU/mL | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Baseline | 4.309 ± 0.687 | 4.383 ± 0.721 |
| Week 12 | 3.844 ± 1.186 | 4.299 ± 0.809 |
| Week 24 | 3.509 ± 1.507 | 4.336 ± 0.732 |
| Week 36 | 3.265 ± 1.661 | 4.272 ± 0.726 |
| Week 48 | 3.078 ± 1.769 | 4.215 ± 0.718 |
| FU Week 24 | 3.37 ± 1.63 | 4.394 ± 0.939 |
Quantitative HBeAg at each visit was averaged among all participants and expressed in log10 PEIU/mL. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| log10 PEIU/mL | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Baseline | 2.344 ± 0.981 |
| Week 12 | 1.62 ± 1.288 |
| Week 24 | 1.802 ± 1.14 |
| Week 36 | 1.561 ± 1.178 |
| Week 48 | 1.429 ± 1.259 |
| FU Week 24 | 1.442 ± 1.416 |
Quantitative HBsAg at each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population.
| log10 IU/mL | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Baseline | 4.225 ± 0.518 |
| Week 12 | 3.829 ± 0.589 |
| Week 24 | 3.515 ± 1.113 |
| Week 36 | 3.282 ± 1.263 |
| Week 48 | 3.215 ± 1.352 |
| FU Week 24 | 3.137 ± 1.463 |
Liver elastography was performed to assess elasticity and extent of hepatic fibrosis. The change in LSM from Baseline to each visit was averaged among all participants in expressed in kilopascals (kPa). Positive changes in LSM values corresponded to an increase in stiffness and hepatic fibrosis. Liver Substudy Population: All participants who consented to participate in the liver elasticity substudy. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| kPa | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|---|---|
| Week 48 | -0.49 ± 2.151 | 0.376 ± 2.719 | -1.517 ± 1.685 |
| FU Week 24 | -1.026 ± 2.269 | -0.72 ± 2.633 | -1.7 ± 1.033 |
The percentage of participants with \>15% drop in weight percentile for age from Baseline to each visit was reported. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Week 30 | 20 |
| Week 36 | 10 |
| FU Week 4 | 10 |
| FU Week 12 | 10 |
| FU Week 24 | 20 |
The difference between the population mean and raw scores was calculated as the height for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| standard deviations | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Baseline | 0.271 ± 1.149 | -0.062 ± 1.17 |
| Week 12 | 0.011 ± 0.258 | -0.006 ± 0.185 |
| Week 24 | -0.04 ± 0.293 | -0.071 ± 0.264 |
| Week 36 | -0.056 ± 0.337 | -0.025 ± 0.328 |
| Week 48 | -0.099 ± 0.365 | -0.013 ± 0.284 |
| FU Week 12 | -0.112 ± 0.404 | -0.037 ± 0.243 |
| FU Week 24 | -0.117 ± 0.429 | -0.079 ± 0.282 |
The difference between the population mean and raw scores was calculated as the weight for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations.Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| standard deviations | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Baseline | 0.106 ± 1.154 | -0.047 ± 1.154 |
| Week 1 | -0.024 ± 0.089 | — |
| Week 2 | -0.023 ± 0.108 | — |
| Week 4 | -0.048 ± 0.158 | — |
| Week 8 | -0.082 ± 0.228 | — |
| Week 12 | -0.09 ± 0.267 | -0.04 ± 0.241 |
| Week 18 | -0.155 ± 0.309 | — |
| Week 24 | -0.165 ± 0.35 | -0.09 ± 0.323 |
| Week 30 | -0.189 ± 0.372 | — |
| Week 36 | -0.192 ± 0.395 | -0.057 ± 0.338 |
| Week 42 | -0.24 ± 0.375 | — |
| Week 48 | -0.214 ± 0.371 | -0.082 ± 0.343 |
| FU Week 4 | -0.156 ± 0.346 | — |
| FU Week 12 | -0.089 ± 0.384 | -0.263 ± 0.333 |
| FU Week 24 | -0.046 ± 0.452 | -0.322 ± 0.325 |
The difference between the population mean and raw scores was calculated as the height for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population.
| standard deviations | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Baseline | 0.586 ± 0.947 |
| Week 12 | 0.07 ± 0.492 |
| Week 24 | 0.262 ± 0.42 |
| Week 36 | 0.3 ± 0.601 |
| Week 48 | 0.19 ± 0.683 |
| FU Week 12 | 0.205 ± 0.611 |
| FU Week 24 | 0.064 ± 0.634 |
The difference between the population mean and raw scores was calculated as the weight for age z-score. Mean absolute values at Baseline were reported. The change from Baseline to each visit was averaged among all participants and expressed in units of standard deviations. Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| standard deviations | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Baseline | 0.187 ± 1.141 |
| Week 1 | -0.044 ± 0.052 |
| Week 2 | -0.023 ± 0.107 |
| Week 4 | 0.049 ± 0.243 |
| Week 8 | -0.041 ± 0.198 |
| Week 12 | 0.012 ± 0.288 |
| Week 18 | -0.018 ± 0.377 |
| Week 24 | -0.089 ± 0.245 |
| Week 30 | -0.094 ± 0.34 |
| Week 36 | 0 ± 0.443 |
| Week 42 | -0.032 ± 0.344 |
| Week 48 | -0.208 ± 0.374 |
| FU Week 4 | -0.054 ± 0.35 |
| FU Week 12 | -0.156 ± 0.29 |
| FU Week 24 | -0.161 ± 0.309 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The percentage of participants with HBeAg seroconversion at 24 weeks after EOT was reported. The 95% CI was calculated by the Pearson-Clopper method. Safety Population.
| percentage of participants | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Percentage of Participants With HBeAg Seroconversion at 24 Weeks After EOT in Group C | 30 ± 6.67 |
The change in quantitative ALT from Baseline to each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). ITT Population. All participants were included in the endpoint analysis. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| factor of ULN | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Week 1 | 0.606 ± 1.565 | — |
| Week 2 | 0.06 ± 2.283 | — |
| Week 4 | 0.564 ± 3.026 | — |
| Week 8 | 0.463 ± 3.225 | — |
| Week 12 | 0.415 ± 3.732 | 0.598 ± 5.934 |
| Week 18 | 0.288 ± 3.332 | — |
| Week 24 | 0.004 ± 3.496 | -0.462 ± 2.311 |
| Week 30 | -0.1 ± 3.163 | — |
| Week 36 | -0.302 ± 2.8 | -0.51 ± 1.835 |
| Week 42 | -0.436 ± 2.732 | — |
| Week 48 | -0.63 ± 2.652 | -0.939 ± 1.914 |
| FU Week 4 | -1.474 ± 2.889 | — |
| FU Week 12 | -0.736 ± 2.972 | — |
| FU Week 24 | -1.302 ± 2.766 | -0.701 ± 2.22 |
The change in quantitative HBeAg from Baseline to each visit was averaged among all participants and expressed in log10 PEIU/mL. ITT Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| log10 PEIU/mL | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Week 12 | -0.583 ± 0.672 | -0.225 ± 0.497 |
| Week 24 | -0.834 ± 0.805 | -0.261 ± 0.612 |
| Week 36 | 1.123 ± 0.91 | -0.3 ± 0.621 |
| Week 48 | -1.28 ± 1.043 | -0.491 ± 0.74 |
| FU Week 24 | -1.24 ± 1.205 | -0.452 ± 0.793 |
The change in quantitative HBsAg from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. ITT Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| log10 IU/mL | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Week 12 | -0.444 ± 1.021 | -0.081 ± 0.356 |
| Week 24 | -0.798 ± 1.343 | -0.032 ± 0.392 |
| Week 36 | -1.051 ± 1.534 | -0.126 ± 0.26 |
| Week 48 | -1.239 ± 1.652 | -0.188 ± 0.285 |
| FU Week 24 | -0.936 ± 1.491 | -0.204 ± 0.316 |
The change in quantitative ALT from Baseline to each visit was averaged among all participants and expressed as a factor of the laboratory-specific ULN (for example, 1 × ULN, 2 × ULN, 3 × ULN). Safety Population. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| factor of ULN | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Week 1 | 0.313 ± 0.414 |
| Week 2 | 0.091 ± 0.991 |
| Week 4 | -0.361 ± 1.566 |
| Week 8 | -0.101 ± 1.895 |
| Week 12 | -0.012 ± 1.613 |
| Week 18 | -0.589 ± 0.996 |
| Week 24 | -0.917 ± 1.31 |
| Week 30 | -0.584 ± 1.73 |
| Week 36 | -0.633 ± 1.455 |
| Week 42 | -1.211 ± 1.05 |
| Week 48 | -1.104 ± 1.084 |
| FU Week 4 | -1.669 ± 0.95 |
| FU Week 12 | -1.283 ± 1.501 |
| FU Week 24 | -1.256 ± 1.757 |
The change in quantitative HBeAg from Baseline to each visit was averaged among all participants and expressed in log10 PEIU/mL. Safety Population. "Number of subjects analyzed" reflects the total number of participants who provided evaluable data at any timepoint. The number of participants who provided evaluable data for the analysis at each timepoint (n) is shown in the table.
| log10 PEIU/mL | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Week 12 | -0.779 ± 0.645 |
| Week 24 | -0.817 ± 0.678 |
| Week 36 | -0.817 ± 0.685 |
| Week 48 | -0.762 ± 0.818 |
| FU Week 24 | -0.742 ± 0.84 |
The change in quantitative HBsAg from Baseline to each visit was averaged among all participants and expressed in log10 IU/mL. Safety Population.
| log10 IU/mL | Group C: PEG-IFN Monotherapy With Advanced Fibrosis |
|---|---|
| Week 12 | -0.397 ± 0.428 |
| Week 24 | -0.71 ± 0.712 |
| Week 36 | -0.943 ± 0.913 |
| Week 48 | -1.01 ± 1.019 |
| FU Week 24 | -1.088 ± 1.141 |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of subjects | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis |
|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Fu Year 1 | 32.7 ± 23.67 | 6.08 ± 1.25 |
| Fu Year 2 | 33.7 ± 24.56 | 6.08 ± 1.25 |
| Fu Year 3 | 46.5 ± 36.55 | 6.08 ± 1.25 |
| Fu Year 4 | 30.7 ± 21.90 | 8.00 ± 2.22 |
| Fu Year 5 | 5.9 ± 2.21 | 0.00 ± 0.00 |
The percentage of participants with loss of HBeAg at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group D: Switch to PEG-IFN Monotherapy |
|---|---|
| Percentage of Participants With Loss of HBeAg at 24 Weeks After the End of Switch Treatment Period: Switch Group | 30.3 (15.59 to 48.71) |
HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.
| percentage of participants | Group D: Switch to PEG-IFN Monotherapy |
|---|---|
| Percentage of Participants With HBsAg Seroconversion at 24 Weeks After the End of Switch Treatment Period: Switch Group | 9.1 (1.92 to 24.33) |
HBeAg seroconversion was defined as loss of HBeAg and the presence of hepatitis B envelope antibody (anti-HBe). The percentage of participants with HBeAg seroconversion at 24 weeks after EOT/POP was reported. The 95 percent (%) confidence interval (CI) was calculated by the Pearson-Clopper method. Intent-to-Treat (ITT) Population: All randomized participants regardless of treatment received.
| percentage of participants | Group D: Switch to PEG-IFN Monotherapy |
|---|---|
| Percentage of Participants With Loss of HBsAg at 24 Weeks After the End of Switch Treatment Period: Switch Group | 12.1 (3.40 to 28.20) |
Normal ALT was defined as ALT ≤ ULN, where each ULN was given by the laboratory at which the sample was analyzed. The percentage of participants with normal ALT at EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group D: Switch to PEG-IFN Monotherapy |
|---|---|
| Percentage of Participants With Normal ALT at 24 Weeks After the End of Switch Treatment Period: Switch Group | 42.4 (25.48 to 60.78) |
HBV DNA was quantified using polymerase chain reaction (PCR) by Roche Taqman. The percentage of participants with HBV DNA \<20,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group D: Switch to PEG-IFN Monotherapy |
|---|---|
| Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) <20,000 International Units Per Milliliter (IU/mL) at 24 Weeks After the End of Switch Treatment Period: Switch Group | 36.4 (20.40 to 54.88) |
HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group D: Switch to PEG-IFN Monotherapy |
|---|---|
| Percentage of Participants With HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group | 27.3 (13.30 to 45.52) |
HBV DNA was quantified using PCR by Roche Taqman. Undetectable HBV DNA was defined as HBV DNA \<29 IU/mL. The percentage of participants with HBV DNA undetectable at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group D: Switch to PEG-IFN Monotherapy |
|---|---|
| Percentage of Participants With HBV DNA Undetectable at 24 Weeks After the End of Switch Treatment Period: Switch Group | 18.2 (6.98 to 35.46) |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group D: Switch to PEG-IFN Monotherapy |
|---|---|
| Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <20,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group | 27.3 (13.30 to 45.52) |
HBeAg seroconversion was defined as loss of HBeAg and the presence of anti-HBe. HBV DNA was quantified using PCR by Roche Taqman. The percentage of participants with combined HBeAg seroconversion and HBV DNA \<2,000 IU/mL at 24 weeks after EOT/POP was reported. The 95% CI was calculated by the Pearson-Clopper method. ITT Population.
| percentage of participants | Group D: Switch to PEG-IFN Monotherapy |
|---|---|
| Percentage of Participants With Combined HBeAg Seroconversion and HBV DNA <2,000 IU/mL at 24 Weeks After the End of Switch Treatment Period: Switch Group | 21.2 (8.98 to 38.91) |
Collected over From Baseline to approximately 4.5 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | 0/101 (0%) | 6/101 (5.9%) | 80/101 (79.2%) |
| Group B: Untreated Control Without Advanced Fibrosis | 0/49 (0%) | 1/49 (2%) | 18/49 (36.7%) |
| Group C: PEG-IFN Monotherapy With Advanced Fibrosis | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Group D: Switch to PEG-IFN Monotherapy | 0/33 (0%) | 2/33 (6.1%) | 21/33 (63.6%) |
| Group A - Long Term Follow-up | 0/101 (0%) | 0/101 (0%) | 25/101 (24.8%) |
| Group B - Long Term Follow-up | 0/49 (0%) | 0/49 (0%) | 6/49 (12.2%) |
| Group C Long Term Follow-up | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Group D - Long Term Follow-up | 0/33 (0%) | 0/33 (0%) | 27/33 (81.8%) |
| Event | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis | Group C: PEG-IFN Monotherapy With Advanced Fibrosis | Group D: Switch to PEG-IFN Monotherapy | Group A - Long Term Follow-up | Group B - Long Term Follow-up | Group C Long Term Follow-up | Group D - Long Term Follow-up |
|---|---|---|---|---|---|---|---|---|
| NephropathyRenal and urinary disorders | 0/101 | 0/49 | 0/10 | 1/33 | 0/101 | 0/49 | 0/10 | 0/33 |
| PneumoniaInfections and infestations | 0/101 | 0/49 | 0/10 | 1/33 | 0/101 | 0/49 | 0/10 | 0/33 |
| Suicidal ideationPsychiatric disorders | 0/101 | 1/49 | 0/10 | 0/33 | 0/101 | 0/49 | 0/10 | 0/33 |
| Alanine aminotransferase increasedInvestigations | 1/101 | 0/49 | 0/10 | 0/33 | 0/101 | 0/49 | 0/10 | 0/33 |
| Aspartate aminotransferase increasedInvestigations | 1/101 | 0/49 | 0/10 | 0/33 | 0/101 | 0/49 | 0/10 | 0/33 |
| OsteochondrosisMusculoskeletal and connective tissue disorders | 1/101 | 0/49 | 0/10 | 0/33 | 0/101 | 0/49 | 0/10 | 0/33 |
| Hepatitis BInfections and infestations | 1/101 | 0/49 | 0/10 | 0/33 | 0/101 | 0/49 | 0/10 | 0/33 |
| Latent tuberculosisInfections and infestations | 1/101 | 0/49 | 0/10 | 0/33 | 0/101 | 0/49 | 0/10 | 0/33 |
| Microsporum infectionInfections and infestations | 1/101 | 0/49 | 0/10 | 0/33 | 0/101 | 0/49 | 0/10 | 0/33 |
| TonsillitisInfections and infestations | 1/101 | 0/49 | 0/10 | 0/33 | 0/101 | 0/49 | 0/10 | 0/33 |
| Event | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis | Group C: PEG-IFN Monotherapy With Advanced Fibrosis | Group D: Switch to PEG-IFN Monotherapy | Group A - Long Term Follow-up | Group B - Long Term Follow-up | Group C Long Term Follow-up | Group D - Long Term Follow-up |
|---|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 49/101 | 5/49 | 8/10 | 17/33 | 1/101 | 0/49 | 0/10 | 0/33 |
| HeadacheNervous system disorders | 30/101 | 2/49 | 4/10 | 11/33 | 1/101 | 0/49 | 0/10 | 17/33 |
| AstheniaGeneral disorders | 10/101 | 0/49 | 0/10 | 4/33 | 0/101 | 0/49 | 0/10 | 10/33 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/101 | 3/49 | 3/10 | 1/33 | 2/101 | 0/49 | 0/10 | 0/33 |
| NauseaGastrointestinal disorders | 7/101 | 0/49 | 3/10 | 1/33 | 0/101 | 0/49 | 0/10 | 2/33 |
| VomitingGastrointestinal disorders | 14/101 | 0/49 | 3/10 | 2/33 | 0/101 | 0/49 | 0/10 | 2/33 |
| Alanine aminotransferase increasedInvestigations | 9/101 | 4/49 | 1/10 | 2/33 | 3/101 | 0/49 | 0/10 | 7/33 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 8/101 | 0/49 | 2/10 | 2/33 | 0/101 | 0/49 | 0/10 | 2/33 |
| Abdominal painGastrointestinal disorders | 19/101 | 0/49 | 0/10 | 4/33 | 0/101 | 0/49 | 0/10 | 2/33 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/101 | 0/49 | 0/10 | 0/33 | 0/101 | 0/49 | 0/10 | 6/33 |
| Age, Continuous(years) | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis | Group C: PEG-IFN Monotherapy With Advanced Fibrosis | Total |
|---|---|---|---|---|
| Mean | 10.41 ± 4.57 | 11.2 ± 5.01 | 6.7 ± 3.27 | 10.55 ± 4.81 |
| Age, Customized(Participants) | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis | Group C: PEG-IFN Monotherapy With Advanced Fibrosis | Total |
|---|---|---|---|---|
| In utero | 0 | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 | 0 |
| Children (2-11 years) | 53 | 20 | 9 | 82 |
| Adolescents (12-17 years) | 48 | 30 | 1 | 79 |
| Adults (18-64 years) | 0 | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Group A: PEG-IFN Monotherapy Without Advanced Fibrosis | Group B: Untreated Control Without Advanced Fibrosis | Group C: PEG-IFN Monotherapy With Advanced Fibrosis | Total |
|---|---|---|---|---|
| Female | 37 | 18 | 2 | 57 |
| Male | 64 | 32 | 8 | 104 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2012 to primary completion in Jul 2015, 35 months.
Results were first posted in Aug 2016, 1 year 1 month after primary completion.
Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 35 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a